Berberine Derivative B68 Promotes Tumor Immune Clearance by Dual-Targeting BMI1 for Senescence Induction and CSN5 for...

Area of Science:

• Oncology
• Immunology
• Drug Discovery

Background:

• Tumor cell senescence can suppress growth but PD-L1 positive cells evade immune clearance.
• Senescent tumor cells secrete factors that promote tumor growth, necessitating new therapeutic strategies.
• Targeting both senescence induction and immune evasion is crucial for effective cancer treatment.

Purpose of the Study:

• To develop a novel therapeutic agent that induces tumor cell senescence and reduces PD-L1 expression.
• To investigate the mechanism of action of the berberine derivative B68 in cancer cells.
• To evaluate the antitumor efficacy and immune-activating potential of B68.

Main Methods:

• Development of berberine derivative B68 targeting BMI1 for senescence induction.
• Investigation of B68's effect on PD-L1 expression via CSN5 targeting.
• Assessment of B68's impact on tumor cell senescence, immune clearance, and antitumor responses in preclinical models.
• Evaluation of synergistic effects with anti-CTLA4 therapy.

Main Results:

• B68 specifically induces tumor cell senescence by targeting BMI1.
• B68 promotes PD-L1 degradation through CSN5, disrupting immune evasion.
• B68 treatment leads to robust antitumor responses and T cell activation.
• Combination therapy with anti-CTLA4 enhances antitumor immunity.

Conclusions:

• The berberine derivative B68 offers a dual-action strategy for cancer treatment by inducing senescence and overcoming immune evasion.
• B68 demonstrates significant potential for activating T cell immunity and suppressing tumor progression.
• These findings support B68 as a promising candidate for further preclinical development in cancer therapy.